--:--:--
Stockwatch Reports
…

News Reports / Healthcare / LQDA

LQDALiquidia Corporation

NasdaqCM · Healthcare · Mkt cap $4.6B · Avg vol 3.52M

$51.40

+3.53 (+7.37%)

Quote as of November 11, 2026, 8:18 AM ET

News Impact Report · Published November 10, 2026, 1:27 PM ET

LQDA: Liquidia Posts Q3 2026 Revenue of $66.3M as Operating Loss Deepens to $71.2M

Share

Filed with the SEC on November 10, 2026 | Form 8-K (Items 2.02, 8.01, 9.01) Current Price: $49.98 | Today's Change: +4.40%

What Happened

Liquidia Corporation filed an 8-K with the SEC on November 10, 2026, disclosing its financial results for the third quarter of fiscal year 2026. The company reported revenue of $66.3 million for Q3 FY2026, while recording a net loss of $38.4 million and a basic and diluted loss per share of $0.97. The operating loss for the quarter came in at $71.2 million, underscoring the significant cost base the company is carrying as it scales its commercial operations.

Why It Matters

The headline revenue figure reflects ongoing commercial momentum — $66.3 million in quarterly revenue signals that Liquidia's product franchise is generating meaningful and growing sales. However, the operating loss of $71.2 million is notably wider than the net loss of $38.4 million, which suggests that below-the-line items — such as interest income, non-cash adjustments, or other non-operating income — are partially offsetting operating-level cash burn. For investors, the key practical question is whether top-line growth is on a trajectory to bring operating losses under control within a foreseeable timeframe. The stock's +4.40% move on the day of this report suggests the market may be interpreting the revenue figure favorably relative to expectations, even as losses remain elevated.

Analysis

Liquidia is clearly in a spend-heavy commercial expansion phase, as evidenced by the gap between its $66.3 million in revenue and its $71.2 million operating loss — implying that operating expenses are running well ahead of gross profit generation. The near-parity between the two figures, however, may itself be a data point worth watching: if revenue continues to scale while cost growth moderates, the path to operating breakeven could be closer than the absolute loss numbers suggest at first glance.

The fact that the net loss ($38.4 million) is materially smaller than the operating loss ($71.2 million) warrants closer attention to the non-operating line items in the full financial statements — the filing's 9.01 exhibit attachments should contain the complete income statement detail. Investors will want to assess whether those offsets are recurring or one-time in nature.

StockWatch initiated coverage on Liquidia in September 2026; this quarterly print provides the first major financial data point since that initiation, and the revenue figure will be a key input into how the commercial ramp is tracking. The +4.40% intraday gain suggests the market is not reading the results as a negative surprise, but the depth of the operating loss remains a critical variable to monitor as the company progresses toward self-sustaining operations.

What to watch next:

  • Sequential revenue growth trend in Q4 FY2026 — the pace of commercial scaling
  • Operating expense trajectory and any guidance updates on the path to breakeven
  • Non-operating line items that explain the gap between operating and net loss
  • Any commentary on the competitive landscape for Liquidia's core product franchise

Disclaimer

This report is a news and informational summary of a publicly filed SEC disclosure. It does not constitute investment advice, an offer to buy or sell securities, or a recommendation of any kind. All financial figures cited are sourced exclusively from the XBRL data accompanying the referenced SEC filing. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on LQDA, published 2026-09-16. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-10. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1819576/000110465926124770/tm2629427d1_8k.htm

StockWatch initiated coverage · September 16, 2026

LQDA: Commercial Inflection in Pulmonary Arterial Hypertension

Commercial Inflection Underway: LQDA shares trade at $69.40, up 5.60% on the day, with a $6.2B market cap on 89.51M shares outstanding. The stock sits well above its 52-week low of $21.15 but below its 52-week high of $93.61, reflecting a market that has repriced the company around the launch trajectory of YUTREPIA (treprostinil) inhalation powder yet remains volatile on competitive and legal headlines. Profitability Has Arrived: Reported EPS of $1.40 implies a trailing earnings base

-25.9%

Read the full report →

-25.9%

Key Data

Last

$49.98

P&L ($)

+$2.10

P&L (%)

+4.40%

Day Range

$46.24 - $50.37

Volume

1.37M

Market Cap

$4.6B

Previous Close

$47.87

Open

$48.73

52 Week Range

$22.31 - $93.61

Shares Outstanding

89.51M

Public Float

65.21M

Average Volume

3.52M

As of November 10, 2026, 1:45 PM ET

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc